Jin Youli

Jin Youli (Jinyouli) is a long-acting pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) developed by CSPC Pharmaceutical Group. It is a biologic agent produced by the covalent conjugation of a 20 kDa polyethylene glycol (PEG) molecule to the N-terminal methionyl residue of recombinant human granulocyte colony-stimulating factor (rhG-CSF). This pegylation modification increases the protein's molecular weight and hydrodynamic radius, significantly extending its plasma half-life by reducing renal clearance. This allows for a single subcutaneous injection per chemotherapy cycle, compared to the daily injections required for standard rhG-CSF. Jin Youli acts as an agonist for the granulocyte colony-stimulating factor receptor (G-CSFR) on hematopoietic progenitor cells and mature neutrophils, stimulating their proliferation, differentiation, and functional activation. It is approved in China for the prevention of chemotherapy-induced neutropenia and is being evaluated in clinical trials, including those led by the Chinese PLA General Hospital, for secondary prevention in specific cancer populations such as advanced pancreatic cancer.

Brand names

Jin YouliJinyouli

Other names

pegfilgrastimpegylated recombinant human granulocyte colony-stimulating factor